Purchase Order 36C24226P0974

<p>Veterans Integrated Service Network 2 awarded a purchase order to Covermymeds Pharmacy LLC for $16,421.95 on August 12, 2026, for Pomalyst 4 mg capsules (NDC 59572-0504-21). Performance occurs in Brooklyn, New York. The order carries a firm fixed-price structure with an ultimate completion date of August 12, 2026.</p>

<p>Veterans Integrated Service Network 2 issued a purchase order to Covermymeds Pharmacy LLC for $16,331.35 on June 5, 2026, for Pomalyst 3 mg capsules for the Brooklyn VAMC outpatient pharmacy. Performance occurs in Memphis, Tennessee. The order carries a firm fixed price and is due for completion by June 26, 2026. No small business set-aside applied.</p>

<p>The Veterans Integrated Service Network 2 issued a purchase order to Covermymeds Pharmacy LLC on July 2, 2026, for Pomalyst 4 mg capsules (NDC 59572-0504-21) valued at $16,421.95 as an emergency procurement. Performance occurs in Memphis, Tennessee, with an ultimate completion date of July 12, 2026. The order is priced on a firm fixed price basis with no small business set-aside.</p>

Covermymeds Pharmacy LLC was awarded a firm fixed price purchase order by the Veterans Integrated Service Network 2 (VISN 2), a civilian component of the Department of Veterans Affairs, for the supply of Pomalyst 4 mg capsules. The contract, awarded on April 17, 2026, carries a ceiling value of $16,421.95 and is scheduled for ultimate completion by July 17, 2026. The pharmaceutical products will be delivered to the place of performance in Memphis, Tennessee. This purchase order represents a...

Veterans Integrated Service Network 2 (Veterans Health Administration, Department of Veterans Affairs) awarded a purchase order to Covermymeds Pharmacy LLC for Polymast medication on August 18, 2026, with a ceiling value of $16,331.35 and completion date of August 31, 2026. No small business set-aside was used. The order is firm fixed price. Place of performance is Brooklyn, New York. The vendor is a for-profit pharmaceutical supplier based in Memphis, Tennessee, competing in full-and-open...

<p>Veterans Integrated Service Network 2 awarded a purchase order to Covermymeds Pharmacy LLC for Revlimid pharmaceutical supply on August 13, 2026, with a ceiling value of $11,314.56 and firm fixed-price pricing. The order carries no small business set-aside. Place of performance is Memphis, Tennessee. The purchase order completes on December 31, 2026.</p>

The Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on August 2, 2026, for POMALYST (pomalidomide) in 2 mg, 3 mg, and 4 mg strengths, with a ceiling value of $199,047.42 under the Pharmaceuticals and Drugs GSA Federal Supply Schedule (FSS-61-IB). The order is firm fixed price with an ultimate completion date of August 31, 2026. Place of performance is Memphis, Tennessee. POMALYST is an immunomodulatory agent supplied to the VA healthcare system for...

<p>Veterans Integrated Service Network 5 issued a BPA call to Bristol-Myers Squibb Company on May 21, 2026, for Pomalidomide (Pomalyst) 4mg capsules, with a ceiling value of $16,421.95 and an ultimate completion date of May 26, 2026. The call is placed under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. Performance occurs in Memphis, Tennessee. The order is firm fixed price with no set-aside designation.</p>

The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on June 18, 2026, for Pomalidomide (Pomalyst) 4 mg capsules with a ceiling value of $16,421.95. The call was issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract, a comprehensive master agreement covering drugs and pharmaceuticals across multiple therapeutic areas including oncology and immunology, with a contract ceiling of $12.278...

<p>The Department of Veterans Affairs, Veterans Integrated Service Network 5, issued a BPA call to Bristol-Myers Squibb Company on May 29, 2026, for POMALYST 2 MG, 3 MG, and 4 MG with a ceiling value of $149,435.80. The call was issued under the Pharmaceuticals and Drugs (FSS-61-IB) Federal Supply Schedule contract. Performance occurs in Memphis, Tennessee, with an ultimate completion date of June 4, 2026. Pricing is firm fixed price with no set-aside designation.</p>